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ABSTRACT
Long term use of high doses of estrogen and the presence of chronic
hyperprolactinemia may, at least in the rat, provoke lesions in the
tuberoinfundibular dopaminergic (TIDA) neurons responsible for the con-
trol of prolactin (Prl) secretion. This occurrence, which is not yet well doc-
umented in humans, may have taken place in a patient on chronic oral
hormonal contraceptive (OC) treatment who was seen for primary
hypothyroidism, hyperprolactinemia and a pituitary mass. After thyroid
hormone replacement, OC withdrawn and bromocriptine treatment, this
patient could not maintain normal Prl levels, unless continuously treated
with a dopaminergic agonist even when MRI was indicative of a normal
situation. Function of TIDA neurons was investigated by TRH test (200µg
IV) performed before and after treatment with 25mg carbidopa plus
250mg L-dopa every 4 hours for one day. Basal TSH was normal
(3.9µU/mL) whereas basal Prl was high (67.5 ng/mL); both TSH and Prl lev-
els appropriately increased after TRH: peaks 31.8µU/mL and 157.8 ng/mL,
respectively. After treatment with carbidopa/L-dopa, basal TSH
(1.6µU/mL) and Prl (34ng/mL) decreased and the response to TRH was
partially blocked (10.3µU/mL and 61ng/mL, respectively). In spite of a
normal response, we discuss the possibility that the persistence of hyper-
prolactinemia is due to lesion of the TIDA neurons produced by the long
term use of high doses of estrogens and by the presence of chronic
hyperprolactinemia. (Arq Bras Endocrinol Metab 2005;49/3:468-472)
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RESUMO
Persistência de Hiperprolactinemia Após Tratamento de Hipotiroidismo
Primário e Suspensão do Uso Prolongado de Estrogênio: os Neurônios
Dopaminérgicos Túberoinfundibulares São Permanentemente Lesados?
Uso prolongado de altas doses de estrogênio e a presença de hiperpro-
lactinemia crônica pode, pelo menos no rato, provocar lesão nos
neurônios dopaminérgicos tuberoinfundibulares (TIDA) responsáveis pelo
controle da secreção de prolactina (Prl). Essa ocorrência, ainda não
bem documentada em humanos, pode ter ocorrido em uma paciente
em tratamento crônico com contraceptivo oral (OC), que veio para
consulta por hipotiroidismo primário, hiperprolactinemia e uma massa
hipofisária. Após reposição de hormônio tiroidiano, suspensão do trata-
mento com o OC e a bromocriptina, essa paciente não manteve níveis
normais de Prl, necessitando tratamento contínuo com agonista
dopaminérgico, mesmo quando a RM da região selar indicava uma situ-
ação normal. A função dos neurônios TIDA foi investigada pelo teste do
TRH (200µg IV), realizado antes e após 25mg de carbidopa e 250mg de
L-dopa a cada 4 horas por um dia. TSH basal (3,9µU/mL) era normal,
enquanto Prl (67,5 ng/mL) estava alta; ambos aumentaram apropriada-
mente após o estímulo com TRH, com picos de 31,8µU/mL (TSH) e
157,8ng/mL (Prl). Após tratamento com carbidopa/L-dopa, os níveis de
apresentação de casos
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TSH (1,6µU/mL) e Prl (34ng/mL) diminuíram e a respos-
ta ao TRH foi parcialmente bloqueada (10,3µU/mL e
61ng/mL, respectivamente). Apesar da resposta nor-
mal, discutimos a possibilidade que a persistência da
hiperprolactinemia é devida a uma lesão dos
neurônios TIDA, produzida pelo longo uso de altas
doses de estrogênios e pela presença de hiperpro-
lactinemia crônica. (Arq Bras Endocrinol Metab
2005;49/3:468-472)
Descritores: Hipotiroidismo; Hiperprolactinemia;
Estrogênio; Dopamina; Hipófise
PROLACTIN SECRETION IS REGULATED by dopamine(DA) produced in the hypothalamus. DA is syn-
thesized by the tuberoinfundibular dopaminergic
(TIDA) neurons which have their cell bodies in the
arcuate and periventricular nuclei of the hypothalamus
and axon terminals in the median eminence (1).
Several studies in the rat have demonstrated the
inhibitory effects of long term treatment with estradi-
ol on the function of TIDA neurons, in contrast with
the stimulatory effects caused by a short term treat-
ment (see (2) for references). The inhibition of TIDA
neurons contributes to hyperprolactinemia associated
with the use of hormonal oral contraceptives (OC)
and estrogen replacement therapy in post-menopause.
Moreover, estrogens are responsible for lactotrope
hyperplasia and prolactin (Prl) hypersecretion occur-
ring during gestation (1).
Frequently, primary hypothyroidism is associat-
ed with hyperprolactinemia which almost never
exceeds 80ng/mL (3). Several mechanisms are possi-
bly involved in this occurrence: reduced secretion of
some Prl inhibitory factors, increased secretion of
TRH and enhanced pituitary sensitivity to tonic TRH
secretion (1). Long lasting primary hypothyroidism
can induce hyperplasia of TSH and Prl producing cells,
causing a radiological image suggestive of a pituitary
tumor (4-8).
In this report, we evaluated a patient with pri-
mary hypothyroidism on OC for 13 years who devel-
oped a pituitary pseudo-tumor associated with greatly
increased TSH and Prl secretion. After L-thyroxine
(L-T4) replacement, bromocriptine treatment and OC
withdrawn, TSH and Prl levels normalized, as well as
the radiological pituitary image. However, to maintain
normal circulating Prl levels it was necessary to treat
the patient chronically with bromocriptine, even after
seven years from the beginning of the L-T4 treatment.
In an attempt to evaluate TIDA neurons function, a
TRH test was performed, both before and after previ-
ous L-dopa plus carbidopa treatment.
We discussed the possibility that the chronic use
of OC and the long lasting hyperprolactinemia might
have produced an irreversible damage to the TIDA
neurons, perpetuating the hyperprolactinemia syn-
drome in the patient.
CASE REPORT
A 35 year-old white woman, came initially to our
observation for amenorrhoea, galactorrhea, headache,
cold intolerance, sleepiness and intestinal constipation.
Physical exam revealed a very dry yellowish skin, dry
and brittle hair, brittle fingernails and pre-tibial
edema. Thyroid was not palpable. Heart frequency
was 64 bpm and blood pressure 100x70mmHg. Her
symptoms have started one year earlier when OC the-
rapy (ethinylestradiol 0.05mg + cyproterone acetate
2mg), continuously used for the last 13 years, was
interrupted. The patient reported menarche when she
was 13, followed by regular 28±3 day cycles and a
normal pregnancy with vaginal delivery. Her mother
was affected by hypothyroidism, systemic arterial
hypertension and hepatic cirrhosis. 
Laboratory results at the initial observation
were: Prl = 243ng/mL (NR <25ng/mL); TSH =
827µU/mL (NR 0.35-4.5µU/mL); thyroxine (T4) =
1.68µg/dL (NR 4.5-12µg/dL); triiodothyronine
(T3) = 35ng/dL (NR 80-210ng/dL); free T4 =
0.5ng/dL (NR 0.8-1.8ng/dL); antithyreoglobulin
<1:100 and antimicrosomal 1/25,600 antibodies;
FSH = 2.8mUI/mL (NR 4-13mUI/mL, follicular
phase; microparticles enzymatic immunoassay); LH =
0.77mUI/mL (NR 1-18mUI/mL, follicular phase);
total cholesterol = 238mg/dL (NR <200mg/dL);
triglyceride = 162mg/dL (NR <150mg/dL); HDL =
62mg/dL (NR >40mg/dL). Prl and LH were mea-
sured by immunoluminescence assay; TSH, T4, T3,
and free T4 by immunofluorimetric assays.
Computerized sellar tomography (CT) showed
a 1.1cm pituitary mass, with suprasellar extension
(figure 1).
Initial replacement therapy with 25µg/day of
L-T4 was followed by a progressive increase up to
100µg/day, together with bromocriptine (1.25mg
twice a day). After 6mo of treatment, menses resumed,
and galactorrhea, headache, and hair fall improved;
TSH (2.6µU/mL) and Prl (12.5ng/mL) normalized.
Pituitary CT scans did not show the presence of any
pituitary mass. Seven years after the beginning of treat-
ment, sellar MRI discloses a normal pituitary image
(figure 2) with normal TSH levels (from 0.8 to
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4.0µU/mL). However, Prl levels, almost normal while
on bromocriptine, increases as soon as treatment is
interrupted (from 33.9 to 77.0ng/mL). Assessment of
macroprolactin was negative.
Due to persistence of hyperprolactinemia, we
investigated the tuberoinfundibular dopaminergic
function by TRH test, performed before and after one
day treatment with L-dopa+carbidopa (see discussion
for the rationale of the test). While maintained on
100µg of L-T4 replacement, the patient was submit-
ted to consecutive (one day apart) TRH tests (200 µg
IV), one before and one after the administration of
25mg carbidopa plus 250mg L-dopa (MSD, São
Paulo) every 4 hours for 24 hours. Blood samples were
collected at -10, 0, and 20, 40, 60 and 80min after
injection. Blood was immediately centrifuged
(3000rpm, for 10min) and the serum obtained frozen
at -20°C, until TSH and Prl were assayed.
As seen in Table 1, basal TSH levels (-10 and 0)
were normal whereas basal Prl was high; both TSH
and Prl levels increased appropriately after TRH stim-
ulation. After carbidopa/L-dopa treatment, basal TSH
levels (-10 and 0) decreased and its response to TRH
was partially blocked. Prl level at -10min was similar to
that observed before treatment, but the level at time 0
was lower. Prl response to TRH was partially blocked
by previous treatment with carbidopa/L-dopa. 
DISCUSSION
It is well known that long term primary hypothy-
roidism may increase TSH and Prl levels (8-11) and
produce pituitary enlargement, documented by neuro-
radiologic imaging (4-8). These alterations are mainly
produced by the high levels of TRH induced by the
decreased negative feedback of thyroid hormones at
the hypothalamic/pituitary level (9). TRH stimulates
the secretion of both TSH and Prl producing hyper-
trophy and hyperplasia of TSH and Prl secreting cells.
In primary hypothyroidism the number and sensitivity
of TRH receptors increases in the thyrotrope and the
lactotrope. TSH and Prl responses to TRH are also
increased (9). After thyroid hormone replacement,
normalization of TSH secretion might be delayed for
months after normalization of T3 and T4 levels (6).
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Figure 1. Computerized sellar tomography showing pituitary
hyperplasia with suprasellar extension.
Figure 2. Magnetic resonance imaging seven years after
the beginning of treatment discloses a normal pituitary
image.
Table 1. Prolactin and TSH responses to TRH (200µg IV) before and 24
hours after treatment with 250mg L-dopa and 25mg carbidopa.
Hormone / time (min) -10 0 20 40 60 80
Prolactin (ng/mL)
Before 68.5 67.5 158 150 104 126
After 64 34 61 59 50 43
TSH (µU/mL)
Before 4.0 3.9 34.5 31.8 17.5 24.4
After 1.6 1.6 10.3 9.2 6.8 5.0
This delay probably represents the time needed for the
thyrotrope mass to regress (5). Recovery of the thy-
roid axis function (basal TSH levels and its response to
TRH) occurs earlier than that of Prl (6,9).
Primary hypothyroidism is associated with a
modest increase of Prl levels in 40% of the patients,
whereas levels higher than 25ng/mL are reached only
in 10% of subjects (11). The patient described in this
study had very high Prl levels (243 ng/mL), a con-
centration never observed in patients with primary
hypothyroidism (11). Moreover, she was persistently
hyperprolactinemic, in spite of the fact that she was
euthyroid in the last 7 years after adequate L-T4
replacement.
The possibility that our patient has developed a
Prl-secreting microadenoma due to long term use of
OC is unlikely because: 1) the initial CT (figure 1)
showed only a homogeneous hyperplasia of the pitu-
itary, and further control images showed a normal pitu-
itary, even when the use of dopamine agonists were
interrupted with resultant increase in Prl levels; 2) it has
not yet been proved that the use of OC may cause a
prolactinoma (see 1 for discussion and references).
We suggest that the use of ethinylestradiol plus
cyproterone acetate for 13 years might have contributed
to produce the hyperprolactinemic syndrome in our
patient. It is known that the use of an OC, or the estro-
gen replacement therapy for menopause, increases 1.5
to 2-fold the circulating Prl levels (12). Estrogens stim-
ulate the synthesis of Prl DNA, mRNA, of Prl itself and
the proliferation of lactotropes (see 1 for references).
Moreover, estrogens enhance the response of Prl to
TRH, increasing the number of TRH receptors in the
lactotrope. It has also been demonstrated in long term
estrogen-treated mice the presence of an irreversible
lesion of TIDA neurons (see 1 for review). Also, in Fis-
cher 344 rats, prolonged exposure to estradiol 17-beta
(E2) has been shown to decrease dopamine synthesis
and release from TIDA neurons (13); these lesions
appear to persist even after E2 removal (14). Since
bromocriptine prevents the tuberoinfundibular neu-
ronal release of dopamine after removal of chronic
estrogen treatment, it is possible that the decline in
TIDA neuronal release of dopamine induced by chron-
ic E2 treatment is at least in part exerted via the marked
hyperprolactinemia in the mouse (15,16).
We have tried to evaluate the integrity of the
TIDA system in our patient using the TRH test
before and after a L-dopa/carbidopa treatment. The
rationale for this test relies on the fact that the
administration of L-dopa, when given alone, increas-
es the amount of dopamine reaching the lactotrope
directly in the pituitary or via TIDA pathways, since
dopa-decarboxylase, the enzyme that transforms
dopamine into L-dopa, is present both at the pitu-
itary and at the hypothalamic level (17). If the com-
pound is administered together with carbidopa, a
dopa-decarboxylase inhibitor, the enzyme is blocked
only at pituitary level, because carbidopa cannot cross
the blood-brain barrier. Hence, the treatment with
L-dopa/carbidopa increases only the pool of
dopamine reaching the pituitary cells from TIDA
pathways. In subjects with normal TIDA pathways,
the degree of Prl inhibition after L-dopa alone or
after carbidopa treatment is similar (17). 
As can be observed in table 1, basal TSH levels
and its response to TRH were normal in our patient;
TSH peak after TRH in an euthyroid subject is 5 to 10
times higher than the basal TSH serum concentration
(18). This demonstrates that the patient was ade-
quately L-T4 replaced and that her high Prl levels were
not due to the presence of primary hypothyroidism.
After L-dopa/carbidopa treatment, both baseline
TSH levels and its response to TRH were decreased.
This is compatible with a normal TIDA neuronal func-
tion in controlling TSH secretion since dopamine
inhibits basal and TRH-stimulated TSH secretion in
normal subjects (19).
The data of the Prl response to TRH before and
after treatment with L-dopa/carbidopa are also shown
in table 1. Before treatment, baseline Prl levels were
increased. After treatment with L-dopa/carbidopa, Prl
levels at time -10 was equal to that observed before
treatment but decreased at time 0. It is possible that
the high Prl level observed at time –10 was due to
stress caused by the patient arriving to the hospital in
order to perform the test. The Prl increase induced by
stress is usually short-lasting and it is not mediated by
dopaminergic pathways (20). 
The 44% decrease observed in baseline Prl lev-
els after L-dopa/carbidopa is similar to that reported
in normal women (21). Before treatment, the TRH
stimulus produced a 134% increase over basal levels; a
Prl response to TRH higher than 100% over baseline
is considered normal (1). After treatment with L-
dopa/carbidopa, Prl response to TRH decreased to
79% of baseline, a result similar to that observed in
normal subjects (22). 
In conclusion, the results obtained in our
patient did not allowed to identify the level at which
the hormonal dysregulation takes place. The patient’s
morphologically normal pituitary gland produces nor-
mal responses to exogenous TRH in terms of both
TSH and Prl secretion, suggesting a hypothalamic
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involvement. However, the TRH test with L-do-
pa/carbidopa does not appear to support the hypoth-
esis of a lesion in the TIDA neurons, produced by the
long term use of estrogen/hyperprolactinemia. It is
possible that inhibition of peripheral dopa-decarboxy-
lase by carbidopa was not complete and that even
modestly increased plasma dopamine levels could have
been sufficient to inhibit Prl stimulation by TRH (22)
making the L-dopa/carbidopa pretreatment unable to
prove a central lesion of the TIDA system. 
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